Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambu ASAMBBY 89 5-Year Yield-on-Cost % is 0.66 as of Jul. 17, 2026, which is 120% above its 10-year median of 0.30. GuruFocus rates AMBBY with a GF Score™ of 89/100 and a GF Value™ of $17.76 (Significantly Undervalued). Among 325 Medical Devices & Instruments companies, Ambu AS ranks worse than 85.23% on this metric.
Ambu AS's yield on cost for the quarter that ended in Mar. 2026 was 0.66.
The historical rank and industry rank for Ambu AS's 5-Year Yield-on-Cost % or its related term are showing as below:
AMBBY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.08 Med: 0.3 Max: 0.67
Current: 0.66
During the past 13 years, Ambu AS's highest Yield on Cost was 0.67. The lowest was 0.08. And the median was 0.30.
AMBBY's 5-Year Yield-on-Cost % is ranked worse than 85.23% of 325
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs AMBBY: 0.66
Ambu AS (OTCPK:AMBBY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ambu AS 5-Year Yield-on-Cost % Related Terms
AMBBY vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Ambu AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambu AS 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ambu AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ambu AS's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Ambu AS is calculated as
Ambu AS (AMBBY) has a 5-Year Yield-on-Cost % of 0.66 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ambu AS and its competitors. This is 120% above median its historical median of 0.30. Over the past decade, Ambu AS's 5-Year Yield-on-Cost % has ranged from 0.08 to 0.67. According to the industry distribution chart, Ambu AS ranks #277 out of 325 companies in the Medical Devices & Instruments industry, placing it in the top 85.2%.
Is Ambu AS's 5-Year Yield-on-Cost % too high?
Ambu AS's current 5-Year Yield-on-Cost % of 0.66 is 120% above median its 10-year median of 0.30. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.67. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.34. Ambu AS's value of 0.66 is 71.8% below this industry median. Based on the distribution chart, Ambu AS ranks #277 out of 325 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ambu AS has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ambu AS ranks #277 out of 325 companies for 5-Year Yield-on-Cost %. This places Ambu AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. Ambu AS's value of 0.66 is 71.8% below this benchmark. Historically, Ambu AS's own 5-Year Yield-on-Cost % has ranged from 0.08 to 0.67 over the past decade. While the company's 10-year median is 0.30 vs. the industry median of 2.34, Ambu AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambu AS's current 5-Year Yield-on-Cost % of 0.66 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ambu AS and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambu AS's current 5-Year Yield-on-Cost % is 0.66, which is 120% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Based on GuruFocus' analysis, Ambu AS (AMBBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.76, compared to a current price of $9.70 — trading 45.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.66, which is 120% above median its 10-year median of 0.30 and 71.8% below the Medical Devices & Instruments industry median of 2.34. Ambu AS's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ambu AS (AMBBY), the current 5-Year Yield-on-Cost % is 0.66 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambu AS (AMBBY) Overvalued in 2026?
Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued.
The current stock price of $9.70 is trading 45.4% below its estimated GF Value™ of $17.76.
GuruFocus considers Ambu AS to be Significantly Undervalued.
Key valuation signals for AMBBY:
5-Year Yield-on-Cost %: 0.66 (120% above median its 10-year median of 0.30)
GF Value™: $17.76 vs. price of $9.70 (45.4% below fair value)
Industry Position: 71.8% below the Medical Devices & Instruments median (#277 of 325)
No single metric tells the full story. See the AMBBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
89GF Score
Get the complete analysis for AMBBY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMBBY has been successfully added to your 
